ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01598129 |
Recruitment Status :
Completed
First Posted : May 15, 2012
Results First Posted : October 2, 2014
Last Update Posted : October 24, 2016
|
Sponsor:
Targovax Oy
Information provided by (Responsible Party):
Targovax ASA ( Targovax Oy )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Malignant Solid Tumour |
Intervention |
Genetic: ONCOS-102 |
Enrollment | 12 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | CGTG-102 |
---|---|
![]() |
CGTG-102 dose escalation CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide. |
Period Title: Overall Study | |
Started | 12 |
Completed | 3 |
Not Completed | 9 |
Reason Not Completed | |
Disease progression | 6 |
Deterioration of WHO status to WHO 4 | 2 |
Withdrawal by Subject | 1 |
Baseline Characteristics
Arm/Group Title | CGTG-102 | |
---|---|---|
![]() |
CGTG-102 dose escalation CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide. |
|
Overall Number of Baseline Participants | 12 | |
![]() |
[Not Specified]
|
|
Age, Continuous
Median (Full Range) Unit of measure: Years |
||
Number Analyzed | 12 participants | |
63
(38 to 68)
|
||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 12 participants | |
Female |
7 58.3%
|
|
Male |
5 41.7%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
Finland | Number Analyzed | 12 participants |
12 | ||
Number of cancer indications
Measure Type: Number Unit of measure: Participants |
||
Number Analyzed | 12 participants | |
9 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Director, Clinical Operations |
Organization: | Oncos Therapeutics |
EMail: | info@oncos.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Targovax ASA ( Targovax Oy ) |
ClinicalTrials.gov Identifier: | NCT01598129 |
Other Study ID Numbers: |
Oncos-C1 |
First Submitted: | April 19, 2012 |
First Posted: | May 15, 2012 |
Results First Submitted: | June 11, 2014 |
Results First Posted: | October 2, 2014 |
Last Update Posted: | October 24, 2016 |